Gradient Investments’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.8M Buy
27,342
+7,757
+40% +$7.93M 0.45% 68
2026
Q1
$18M Sell
19,585
-884
-4% -$896K 0.28% 108
2025
Q4
$22M Buy
20,469
+19,634
+2,351% +$18.8M 0.35% 89
2025
Q3
$637K Buy
835
+166
+25% +$124K 0.01% 289
2025
Q2
$522K Sell
669
-1
-0.1% -$777 0.01% 290
2025
Q1
$553K Buy
670
+298
+80% +$248K 0.01% 230
2024
Q4
$287K Sell
372
-6
-2% -$4.97K 0.01% 263
2024
Q3
$335K Sell
378
-135
-26% -$121K 0.01% 254
2024
Q2
$464K Buy
513
+112
+28% +$89.6K 0.01% 247
2024
Q1
$312K Sell
401
-497
-55% -$354K 0.01% 254
2023
Q4
$523K Buy
898
+225
+33% +$131K 0.01% 247
2023
Q3
$362K Sell
673
-9
-1% -$4.64K 0.01% 260
2023
Q2
$320K Buy
682
+114
+20% +$47.8K 0.01% 279
2023
Q1
$195K Buy
568
+89
+19% +$30K 0.01% 295
2022
Q4
$175K Sell
479
-24
-5% -$8.51K 0.01% 314
2022
Q3
$163K Sell
503
-658
-57% -$208K 0.01% 305
2022
Q2
$376K Sell
1,161
-22,018
-95% -$6.61M 0.01% 249
2022
Q1
$6.64M Sell
23,179
-5,495
-19% -$1.41M 0.17% 133
2021
Q4
$7.92M Sell
28,674
-1,330
-4% -$337K 0.2% 126
2021
Q3
$6.93M Buy
30,004
+2,073
+7% +$512K 0.19% 128
2021
Q2
$6.41M Buy
27,931
+1,926
+7% +$387K 0.19% 128
2021
Q1
$4.86M Sell
26,005
-56,975
-69% -$11.1M 0.16% 134
2020
Q4
$12.3M Sell
82,980
-1,003
-1% -$150K 0.52% 49
2020
Q3
$12.4M Buy
83,983
+25,503
+44% +$3.95M 0.52% 49
2020
Q2
$9.6M Sell
58,480
-16,051
-22% -$2.46M 0.44% 66
2020
Q1
$10.3M Sell
74,531
-8,217
-10% -$1.13M 0.56% 44
2019
Q4
$10.9M Buy
82,748
+1,878
+2% +$218K 0.48% 55
2019
Q3
$9.04M Sell
80,870
-8,236
-9% -$917K 0.44% 66
2019
Q2
$9.87M Buy
89,106
+86,488
+3,304% +$10.2M 0.51% 41
2019
Q1
$340K Buy
2,618
+1,881
+255% +$229K 0.02% 209
2018
Q4
$85K Sell
737
-184
-20% -$20.6K 0.01% 279
2018
Q3
$99K Hold
921
0.01% 283
2018
Q2
$79K Sell
921
-12
-1% -$986 ﹤0.01% 287
2018
Q1
$72K Sell
933
-292
-24% -$23.5K ﹤0.01% 299
2017
Q4
$103K Buy
+1,225
New +$104K 0.01% 279
2017
Q3
Sell
-1,147
Closed -$94K 505
2017
Q2
$94K Sell
1,147
-84,195
-99% -$6.87M 0.01% 260
2017
Q1
$7.18M Buy
85,342
+6,523
+8% +$522K 0.55% 28
2016
Q4
$5.8M Buy
78,819
+78,360
+17,072% +$5.84M 0.51% 40
2016
Q3
$37K Hold
459
﹤0.01% 280
2016
Q2
$36K Buy
459
+75
+20% +$5.65K ﹤0.01% 283
2016
Q1
$28K Hold
384
﹤0.01% 311
2015
Q4
$32K Sell
384
-2
-0.5% -$166 ﹤0.01% 284
2015
Q3
$32K Sell
386
-44
-10% -$3.71K ﹤0.01% 266
2015
Q2
$36K Buy
430
+53
+14% +$4.04K ﹤0.01% 268
2015
Q1
$27K Hold
377
﹤0.01% 302
2014
Q4
$26K Hold
377
﹤0.01% 289
2014
Q3
$24K Hold
377
﹤0.01% 264
2014
Q2
$23K Sell
377
-416
-52% -$24.8K ﹤0.01% 277
2014
Q1
$47K Buy
793
+96
+14% +$5.36K 0.01% 207
2013
Q4
$36K Sell
697
-26,973
-97% -$1.35M 0.01% 254
2013
Q3
$1.39M Buy
27,670
+27,203
+5,825% +$1.42M 0.44% 70
2013
Q2
$23K Buy
+467
New +$25.4K 0.01% 218

Other funds holding LLY

Gradient Investments's LLY Position: Q2 2026 in Review

Gradient Investments increased its Eli Lilly (LLY) stake by 40% in Q2 2026, buying an estimated $7.93M and bringing the position to 27,342 shares worth $32.8M. The position accounts for 0.45% of the portfolio, ranked #68.

Gradient Investments first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Gradient Investments held 27,342 shares of Eli Lilly worth $32.8M as of Q2 2026.
  • Gradient Investments bought 7,757 Eli Lilly shares in Q2 2026, an estimated $7.93M.
  • Eli Lilly made up 0.45% of Gradient Investments's portfolio in Q2 2026, its #68 holding.
  • Gradient Investments first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Gradient Investments's 13F filing for Q2 2026, filed 8 Jul 2026.